dapoxetine + lidocaine

Dapoxetine + lidocaine is a combination therapeutic regimen being investigated for the treatment of lifelong premature ejaculation (PE), particularly in patients who are refractory to dapoxetine monotherapy. The regimen consists of oral dapoxetine, a short-acting selective serotonin reuptake inhibitor (SSRI), and a topical 5% lidocaine spray. Dapoxetine acts centrally by inhibiting the serotonin transporter (SERT), thereby increasing serotonin levels and delaying the ejaculatory reflex. Lidocaine acts as a local anesthetic by blocking voltage-gated sodium channels in the sensory nerve fibers of the penis, providing a peripheral desensitizing effect. This dual-action approach aims to provide superior efficacy compared to monotherapy by targeting both central and peripheral pathways involved in ejaculation.

Other names

dapoxetine plus lidocaine spray